Author:
Tatsuno Saori,Doi Hiroshi,Okada Wataru,Inoue Eri,Nakamatsu Kiyoshi,Tanooka Masao,Tanaka Masahiro,Nishimura Yasumasa
Abstract
AbstractThe risk factors for severe radiation pneumonitis (RP) in patients with lung cancer who undergo rotating gantry intensity-modulated radiation therapy (IMRT) using volumetric modulated arc therapy (VMAT) or helical tomotherapy (HT) are poorly understood. Fifty-two patients who received rotating gantry IMRT for locally advanced lung cancer were included in this retrospective study. In total, 31 and 21 patients received VMAT and HT, respectively. The median follow-up duration was 14 months (range, 5.2–33.6). Twenty (38%) and eight (15%) patients developed grade ≥ 2 and ≥ 3 RP, respectively. In multivariate analysis, lung V5 ≥ 40% was associated with grade ≥ 2 RP (P = 0.02), and past medical history of pneumonectomy and total lung volume ≤ 3260 cc were independently associated with grade ≥ 3 RP (P = 0.02 and P = 0.03, respectively). Rotating gantry IMRT was feasible and safe in patients with lung cancer undergoing definitive radiotherapy. Reducing lung V5 may decrease the risk of symptomatic RP, and care should be taken to avoid severe RP after radiotherapy in patients with a past medical history of pneumonectomy and small total lung volume.
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer Version 5. 2021 https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 01 July 2021.
2. Park, K. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS SSO and TOS. Ann. Oncol. 31, 191–201 (2020).
3. Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage iii non–small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
4. Faivre-Finn, C. et al. Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC—an update from the PACIFIC trial. J. Thorac. Oncol. 16, 860–867 (2021).
5. Palma, D. A. et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 85, 444–450 (2013).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献